

**PLEASE STAMP TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING:**

In Re Application of: Sanjay D. KHARE

Serial No.: 10/748,112

Filed: December 29, 2003

For: COMBINATION THERAPY WITH CO-STIMULATORY FACTORS



---

1. Information Disclosure Statement Under 37 C.F.R. § 1.97(b) (2 pages);
2. Form PTO 1449 (20 pages); and
3. Copies of three hundred and fifteen (315) documents (Boxes 1-4).

---

Dated: August 19, 2004

Docket No.: 06843.0052-00000

MPB/RBS/nyf

**PLEASE RETURN TO REGIONAL DESK -- CA OFFICE**

(Due Date: None)



PATENT  
Customer Number: 22,852  
Attorney Docket No. 06843.0052-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Sanjay D. KHARE ) Group Art Unit: 1646  
Application No.: 10/748,112 ) Examiner: Not Yet Assigned  
Filed: December 29, 2003 ) Confirmation No. 1751  
For: COMBINATION THERAPY WITH )  
CO-STIMULATORY FACTORS )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner all the documents listed on the attached Form PTO 1449. This Information Disclosure Statement is being filed, to the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents that are not U.S. Patent publications are enclosed.

Applicant respectfully requests that the Examiner consider all the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: August 18, 2004

By:   
Michael R. Albrecht  
Reg. No. 54,956  
Customer No. 22,852



## INFORMATION DISCLOSURE CITATION

Atty. Docket No. 06843.0052-00000	Appln. No. 10/748,112
Applicant Sanjay D. KHARE	
Filing Date December 29, 2003	Group: 1646

## U.S. PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	N	2,512,572	06/20/1950	Smith et al.			
	N	3,773,919	11/20/1973	Boswell et al.			
	N	3,892,801	07/01/1975	Kazan			
	N	3,989,703	11/02/1976	Niculescu-Duvăz et al.			
	N	4,057,548	11/08/1977	Wiecko			
	N	4,067,867	01/10/1978	Wiecko			
	N	4,079,056	03/14/1978	Piper et al.			
	N	4,080,325	03/21/1978	Ellard			
	N	4,136,101	01/23/1979	Kazan			
	N	4,179,337	12/18/1979	Davis et al.			
	N	4,224,446	09/23/1980	Catalucci			
	N	4,289,872	09/15/1981	Denkewalter et al.			
	N	4,306,064	12/15/1981	Ellard et al.			
	N	4,374,987	02/22/1983	Singh et al.			
	N	4,421,913	12/20/1983	Ellard et al.			
	N	4,474,893	10/02/1984	Reading			
	N	4,619,794	10/28/1986	Hauser			
	N	4,699,880	10/13/1987	Goldstein			
	N	4,767,859	08/30/1988	Zimmermann			
	N	4,816,567	03/28/1989	Cabilly et al.			
	N	4,935,343	06/19/1990	Allison et al.			
	N	4,946,778	08/07/1990	Ladner et al.			
	N	4,970,154	11/13/1990	Chang			
	N	5,075,222	12/24/1991	Hannum et al.			
	N	5,106,627	04/21/1992	Aebischer et al.			
	N	5,136,021	08/04/1992	Dembinski et al.			

\* Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

## U.S. PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	N	5,151,510	09/29/1992	Stec et al.			
	N	5,180,812	01/19/1993	Dower et al.			
	N	5,229,490	07/20/1993	Tam			
	N	5,260,203	11/09/1993	Ladner et al.			
	N	5,319,071	06/07/1994	Dower et al.			
	N	5,344,915	09/06/1994	LeMaire et al.			
	N	5,359,032	10/25/1994	Dayer et al.			
	N	5,359,037	10/25/1994	Wallach et al.			
	N	5,399,346	03/21/1995	Anderson et al.			
	N	5,464,937	11/07/1995	Sims et al.			
	N	5,488,032	01/30/1996	Dower et al.			
	N	5,492,888	02/20/1996	Dower et al.			
	N	5,547,970	08/20/1996	Weithmann et al.			
	N	5,512,544	04/30/1996	Wallach et al.			
	N	5,593,875	01/14/1997	Wurm et al.			
	N	5,608,035	3/4/1997	Yanofsky et al.			
	N	5,633,145	05/27/1997	Feldmann et al.			
	N	5,641,673	06/24/1997	Haseloff et al.			
	N	5,672,344	09/30/1997	Kelley et al.			
	N	5,674,704	10/07/1997	Goodwin et al.			
	N	5,676,954	10/14/1997	Brigham			
	N	5,679,559	10/21/1997	Kim et al.			
	N	5,695,953	12/09/1997	Wallach et al.			
	N	5,747,444	05/05/1998	Haskill et al.			
	N	5,770,197	06/23/1998	Linsley et al.			
	N	5,773,253	06/30/1998	Linsley et al.			

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

## U.S. PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	N	5,807,862	09/15/1998	Klein et al.			
	N	5,808,029	09/15/1998	Brockhaus et al.			
	N	5,811,261	09/22/1998	Wallach et al.			
	N	5,817,822	10/06/1998	Nantermet et al.			
	N	5,830,742	11/03/1998	Black et al.			
	N	5,834,435	11/10/1998	Slesarev			
	N	5,843,905	12/01/1998	Singh et al.			
	N	5,844,095	12/01/1998	Linsley et al.			
	N	5,851,556	12/22/1998	Breton et al.			
	N	5,851,795	12/22/1998	Linsley et al.			
	N	5,853,977	12/29/1998	Dalie et al.			
	N	5,854,003	12/29/1998	Rothe et al.			
	N	5,856,161	01/05/1999	Aggarwal et al.			
	N	5,859,207	01/12/1999	Johnson et al.			
	N	5,863,926	01/26/1999	Christensen et al.			
	N	5,866,576	02/02/1999	Underiner et al.			
	N	5,866,616	02/02/1999	Christensen et al.			
	N	5,869,315	02/09/1999	Talanian et al.			
	N	5,869,511	02/09/1999	Cohan et al.			
	N	5,869,660	02/09/1999	Adams et al.			
	N	5,869,677	02/09/1999	Christensen et al.			
	N	5,872,095	02/16/1999	Haskill et al.			
	N	5,872,146	02/16/1999	Baxter et al.			
	N	5,877,151	03/02/1999	Pereira			
	N	5,877,180	03/02/1999	Linden et al.			
	N	5,877,200	03/02/1999	Muller			

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

## U.S. PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	N	5,877,222	03/02/1999	McGrath			
	N	5,886,010	03/23/1999	Mori et al.			
	N	5,891,883	04/06/1999	Christensen et al.			
	N	5,912,324	06/15/1999	Okamura et al.			
	N	5,914,253	06/22/1999	Okamura et al.			
	N	5,929,117	07/27/1999	Muller et al.			
	N	5,932,208	08/03/1999	Chedid et al.			
	N	5,942,607	08/24/1999	Freeman et al.			
	N	5,948,638	09/07/1999	Lin et al.			
	N	5,952,320	09/14/1999	Davidsen et al.			
	N	5,955,435	09/21/1999	Baxter et al.			
	N	5,955,476	09/21/1999	Muller et al.			
	N	5,955,480	09/21/1999	Chang			
	N	5,962,481	10/05/1999	Levin et al.			
	N	5,965,564	10/12/1999	Bianco et al.			
	N	5,981,724	11/09/1999	Armitage et al.			
	N	5,990,119	11/23/1999	Christensen et al.			
	N	5,994,351	11/30/1999	Robinson et al.			
	N	6,025,376	02/15/2000	Laurent et al.			
	N	6,040,327	03/21/2000	De Nanteuil et al.			
	N	6,054,487	04/25/2000	Sekut et al.			
	N	6,060,283	05/09/2000	Okura et al.			
	N	6,090,382	07/18/2000	Salfeld et al.			
	N	6,258,562 B1	07/10/2001	Salfeld et al.			
	N	6,294,170 B1	09/25/2001	Boone et al.			
	N	6,344,457 B1	02/05/2002	Jeanpetit et al.			

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No. 06843.0052-00000	Appln. No. 10/748,112
Applicant Sanjay D. KHARE	
Filing Date December 29, 2003	Group: 1646

## U.S. PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	N	6,344,464 B1	02/05/2002	Bourrie et al			
	N	6,355,779 B1	03/12/2002	Goodwin et al.			
	N	6,440,693 B1	08/27/2002	Hauptmann et al.			
	N	6,445,283 B1	09/03/2002	Pang et al.			
	N	6,492,370 B1	12/10/2002	Mita et al.			
	N	US 2003/0064480 A1		Lauffer et al.			04/30/2002
	N	US 2004/0080919 A1		Behammer			02/13/2003

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	DE 4219626 A1	12/23/1993	DE			Abstract only
	Y	AU-A-73636/91	10/03/1991	AU			
	Y	EP 0 036 676 B2	09/30/1981	EP			
	Y	EP 0 058 481 B2	08/25/1982	EP			
	Y	EP 0 133,988 A2	03/13/1985	EP			Abstract only
	Y	EP 0 143 949 B1	06/12/1985	EP			
	Y	EP 0 220 063 A2	04/29/1987	EP			
	Y	EP 0 267 611 B1	05/18/1988	EP			
	Y	EP 0 308 378 B1	03/22/1989	EP			
	Y	EP 0 364 778 B1	04/25/1990	EP			
	Y	EP 0 398 327 B1	11/22/1990	EP			
	Y	EP 0 412 486 B1	02/13/1991	EP			
	Y	EP 0 418 014 B1	03/20/1991	EP			
	Y	EP 0 422 339 B1	04/17/1991	EP			
	Y	EP 0 433 900 B1	06/26/1991	EP			

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl. <sup>‡</sup>	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	EP 0 445 228 B1	09/11/1991	EP			
	Y	EP 0 512 528 B1	11/11/1992	EP			
	Y	EP 0 526 905 A2	02/10/1993	EP			
	Y	EP 0 526 905 A3	02/10/1993	EP			
	Y	EP 0 534 978 B1	04/07/1993	EP			
	Y	EP 0 542 795 B1	05/26/1993	EP			
	Y	EP 0 550 376 A1	07/07/1993	EP			
	Y	EP 0 568 928 B1	11/10/1993	EP			
	Y	EP 0 614 984 B1	09/14/1994	EP			
	Y	EP 0 623 674 A1	11/09/1994	EP			
	Y	EP 0 648 783 B1	04/19/1995	EP			
	Y	EP 0 663 210 A2	07/19/1995	EP			
	Y	EP 0 663 210 A3	07/19/1995	EP			
	Y	EP 0 664 128 A1	07/26/1995	EP			
	Y	EP 0 712 931 B1	05/22/1996	EP			
	Y	EP 0 731 791 B1	09/18/1996	EP			
	Y	EP 0 741 707 B1	11/13/1996	EP			
	Y	EP 0 818 439 B1	01/14/1998	EP			
	Y	EP 0 850 952 A1	07/01/1998	EP			
	Y	EP 0 853 083 B1	07/15/1998	EP			
	Y	EP 0 864 585 A1	09/16/1998	EP			
	Y	EP 0 880 970 A1	12/02/1998	EP			
	Y	EP 0 882 714 A1	12/09/1998	EP			
	Y	EP 0 895 988 B1	02/10/1999	EP			
	Y	EP 0 939 121 B1	09/01/1999	EP			
	Y	EP 0 943 616 A1	09/22/1999	EP			

<sup>‡</sup> Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No. 06843.0052-00000		Appln. No. 10/748,112	
Applicant Sanjay D. KHARE			
Filing Date	December 29, 2003	Group:	1646

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	EP 0 962 531 A2	12/08/1999	EP			
	Y	EP 0 962 531 A3	12/08/1999	EP			
	Y	EP 0 974 600 A2	01/26/2000	EP			
	Y	EP 0 974 600 A3	01/26/2000	EP			
	Y	EP 1 008 346 A1	06/14/2000	EP			
	Y	EP 1 110 969 A1	06/27/2001	EP			
	Y	FR 2706772	12/30/1994	FR			Abstract only
	Y	GB 2 218 101 A	11/08/1989	GB			
	Y	GB 2 246 569 A	02/05/1992	GB			
	Y	GB 2 326 881 A	01/06/1999	GB			
	Y	JP 10130149 A2	05/19/1998	JP			Abstract
	Y	JP 10147531 A2	06/02/1998	JP			Abstract
	Y	JP 10231285 A2	09/02/1998	JP			Abstract
	Y	JP 10259140 A2	09/29/1998	JP			Abstract
	Y	JP 10316570 A2	12/02/1998	JP			Abstract
	Y	JP 11001481 A	01/06/1999	JP			Abstract
	Y	WO 00/24782	05/04/2000	PCT			
	Y	WO 00/47740	08/17/2000	PCT			
	Y	WO 00/67034	11/09/2000	PCT			
	Y	WO 01/39722 A2	06/07/2001	PCT			
	Y	WO 01/85782 A2	11/15/2001	PCT			
	Y	WO 01/87977 A2	11/20/2001	PCT			
	Y	WO 01/92337 A2	12/06/2001	PCT			
	Y	WO 02/02638 A2	01/10/2002	PCT			
	Y	WO 02/002638 A3	01/10/2002	PCT			

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	WO 02/092620 A2	11/21/2002	PCT			
	Y	WO 88/01649	03/10/1988	PCT			
	Y	WO 90/05541	05/31/1990	PCT			
	Y	WO 90/06371	06/14/1990	PCT			Abstract only
	Y	WO 91/03553	03/21/1991	PCT			
	Y	WO 91/08285	06/13/1991	PCT			
	Y	WO 91/17184	11/14/1991	PCT			
	Y	WO 91/17249	11/14/1991	PCT			
	Y	WO 92/00092	01/09/1992	PCT			
	Y	WO 92/01002	01/23/1992	PCT			Abstract only
	Y	WO 92/13095	08/06/1992	PCT			
	Y	WO 92/16221	10/01/1992	PCT			
	Y	WO 93/00431	01/07/1993	PCT			
	Y	WO 93/07863	04/29/1993	PCT			
	Y	WO 93/08207	04/29/1993	PCT			
	Y	WO 93/15722	08/19/1993	PCT			
	Y	WO 93/19767	10/14/1993	PCT			
	Y	WO 93/19777	10/14/1993	PCT			
	Y	WO 93/21259	10/28/1993	PCT			
	Y	WO 93/21946	11/11/1993	PCT			
	Y	WO 93/24135	12/09/1993	PCT			
	Y	WO 94/02627	02/03/1994	PCT			Abstract only
	Y	WO 94/05691	03/17/1994	PCT			
	Y	WO 94/06457	03/31/1994	PCT			
	Y	WO 94/20069	09/15/1994	PCT			
	Y	WO 94/20517	09/15/1994	PCT			

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	WO 94/21235	09/29/1994	PCT			
	Y	WO 94/26290	11/24/1994	PCT			
	Y	WO 94/28912	12/22/1994	PCT			
	Y	WO 95/01997	01/19/1995	PCT			
	Y	WO 95/04045	02/09/1995	PCT			
	Y	WO 95/09653	04/13/1995	PCT			
	Y	WO 95/34326	12/21/1995	PCT			
	Y	WO 96/09323	03/28/1996	PCT			
	Y	WO 96/11209	04/18/1996	PCT			
	Y	WO 96/12735	05/02/1996	PCT			
	Y	WO 96/20926	07/11/1996	PCT			
	Y	WO 96/22793	08/01/1996	PCT			
	Y	WO 96/23067	08/01/1996	PCT			
	Y	WO 96/25861	08/29/1996	PCT			
	Y	WO 96/28546	09/19/1996	PCT			
	Y	WO 96/32478	10/17/1996	PCT			
	Y	WO 96/33172	10/24/1996	PCT			
	Y	WO 96/35711	11/14/1996	PCT			
	Y	WO 96/38150	12/05/1996	PCT			
	Y	WO 96/40907	12/19/1996	PCT			
	Y	WO 96/40918	12/19/1996	PCT			
	Y	WO 96/40958	12/19/1996	PCT			
	Y	WO 97/08174	03/06/1997	PCT			
	Y	WO 97/11668	04/03/1997	PCT			
	Y	WO 97/12244	04/03/1997	PCT			
	Y	WO 97/12902	04/10/1997	PCT			

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	WO 97/18207	05/22/1997	PCT			
	Y	WO 97/23457	07/03/1997	PCT			
	Y	WO 97/24441	07/10/1997	PCT			
	Y	WO 97/28267	08/07/1997	PCT			
	Y	WO 97/28828	08/14/1997	PCT			
	Y	WO 97/34631	09/25/1997	PCT			
	Y	WO 97/37973	10/16/1997	PCT			
	Y	WO 97/37974	10/16/1997	PCT			
	Y	WO 97/43250	11/20/1997	PCT			
	Y	WO 97/47599	12/18/1997	PCT			
	Y	WO 98/01555	01/15/1998	PCT			
	Y	WO 98/17661	04/30/1998	PCT			
	Y	WO 98/21957	05/28/1998	PCT			
	Y	WO 98/24463	06/11/1998	PCT			
	Y	WO 98/30541	07/16/1998	PCT			
	Y	WO 98/32733	07/30/1998	PCT			
	Y	WO 98/33513	08/06/1998	PCT			
	Y	WO 98/38859	09/11/1998	PCT			
	Y	WO 98/39315	09/11/1998	PCT			
	Y	WO 98/39316	09/11/1998	PCT			
	Y	WO 98/39326	09/11/1998	PCT			
	Y	WO 98/39329	09/11/1998	PCT			
	Y	WO 98/39361	09/11/1998	PCT			
	Y	WO 98/41232	09/24/1998	PCT			
	Y	WO 98/42325	10/01/1998	PCT			
	Y	WO 98/42659	10/01/1998	PCT			

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	WO 98/43946	10/08/1998	PCT			
	Y	WO 98/43959	10/08/1998	PCT			
	Y	WO 98/44940	10/15/1998	PCT			
	Y	WO 98/45268	10/15/1998	PCT			
	Y	WO 98/47892	10/29/1998	PCT			
	Y	WO 98/51665	11/19/1998	PCT			
	Y	WO 98/52937	11/26/1998	PCT			
	Y	WO 98/52948	11/26/1998	PCT			
	Y	WO 98/53842	12/03/1998	PCT			
	Y	WO 98/56377	12/17/1998	PCT			
	Y	WO 98/56756	12/17/1998	PCT			
	Y	WO 98/56788	12/17/1998	PCT			
	Y	WO 98/57936	12/23/1998	PCT			
	Y	WO 98/58965	12/30/1998	PCT			
	Y	WO 99/00363	01/07/1999	PCT			
	Y	WO 99/00364	01/07/1999	PCT			
	Y	WO 99/01139	01/14/1999	PCT			
	Y	WO 99/01449	01/14/1999	PCT			
	Y	WO 99/02510	01/21/1999	PCT			
	Y	WO 99/03837	01/28/1999	PCT			
	Y	WO 99/04793	02/04/1999	PCT			Abstract only
	Y	WO 99/06041	02/11/1999	PCT			
	Y	WO 99/06042	02/11/1999	PCT			
	Y	WO 99/06410	02/11/1999	PCT			
	Y	WO 99/06426	02/11/1999	PCT			
	Y	WO 99/07679	02/18/1999	PCT			

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	WO 99/07704	02/18/1999	PCT			
	Y	WO 99/08688	02/25/1999	PCT			
	Y	WO 99/09022	02/25/1999	PCT			
	Y	WO 99/09063	02/25/1999	PCT			
	Y	WO 99/09965	03/04/1999	PCT			
	Y	WO 99/22760	05/14/1999	PCT			
	Y	WO 99/36415	07/22/1999	PCT			
	Y	WO 99/36426	07/22/1999	PCT			
	Y	WO 99/36541	07/22/1999	PCT			
	Y	WO 99/37625	07/29/1999	PCT			
	Y	WO 99/37772	07/29/1999	PCT			
	Y	WO 99/37773	07/29/1999	PCT			
	Y	WO 99/37818	07/29/1999	PCT			
	Y	WO 99/46248	09/16/1999	PCT			
	Y	WO 99/47154	09/23/1999	PCT			
	Y	WO 99/47545	09/23/1999	PCT			
	Y	WO 99/47672	09/23/1999	PCT			
	Y	WO 99/58674	11/18/1999	PCT			

Examiner Initial*	Copy Encl.‡	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Aguet et al., "Various human interferon $\alpha$ subclasses cross-react with common receptors: their binding affinities correlate with their specific biological activities," <i>Virology</i> , 132:211-216 (1984).
	Y	Akiba et al., "CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells," <i>J. Immunol.</i> , 162:7058-7066 (1999).
	Y	Al-Janadi et al., "Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases," <i>J. Clin. Immunology</i> , 13:58-67 (1993).

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl.‡	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Aruffo et al., "Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system," <i>Proc. Natl. Acad. Sci. USA</i> , 84:8573-8579 (1987).
	Y	Auricchio et al., "Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column," <i>Human Gene Therapy</i> , 12:71-76 (2001).
	Y	Ausubel et al., eds., <i>Current Protocols in Molecular Biology</i> , Vols. 1, 2, 3 and 4, John Wiley & Sons, Inc. (1999) TABLE OF CONTENTS.
	Y	Bach et al., "The IFNy receptor: a paradigm for cytokine receptor signaling," <i>Annu. Rev. Immunol.</i> , 15:563-591 (1997).
	Y	Barrera et al., "Effects of antiheumatic agents on cytokines," <i>Seminars in Arthritis and Rheumatism</i> , 25:234-253 (1996).
	Y	Bischoff et al., "Preliminary model for methotrexate pharmacokinetics," <i>J. Pharm. Sci.</i> , 59(2) :149-154 (1970).
	Y	Boulianne et al., "Production of functional chimaeric mouse/human antibody," <i>Nature</i> , 312: 643-646 (1984).
	Y	Bowie et al., "A method to identify protein sequences that fold into a known three-dimensional structure," <i>Science</i> , 253:164-170 (1991).
	Y	Brenner et al., "Population statistics of protein structures: lessons from structural classifications," <i>Curr. Opn. Struct. Biol.</i> , 7:369-376 (1997).
	Y	Brodeur et al., "Mouse-human myeloma partners for the production of heterohybridomas," <i>Production of Heterohybridomas</i> , Ch. 4, pp. 51-63, Marcel Dekker, Inc., (1987).
	Y	Brody et al., "Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin-1 $\beta$ to the interleukin-1 receptor on target cells," <i>Eur. J. Clin. Chem. Clin. Biochem.</i> , 31:667-674 (1993).
	Y	Brüggemann et al., "Designer mice: the production of human antibody repertoires in transgenic animals," <i>Year in Immunol.</i> , 7:33-40 (1993).
	Y	Brunet et al., "A new member of the immunoglobulin superfamily--CTLA-4," <i>Nature</i> , 328:267-270 (1987).
	Y	Buschle et al., "Interferon $\gamma$ inhibits apoptotic cell death in B cell chronic lymphocytic leukemia," <i>J. Exp. Med.</i> , 177:213-218 (1993).
	Y	Cabilly et al., "Generation of antibody activity from immunoglobulin polypeptide chains produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 81:3273-3277 (1984).
	Y	Camerini et al., "The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family," <i>J. Immunol.</i> , 147:3165-3169 (1991).

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl.‡	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Chothia et al., "Canonical structures for the hypervariable regions of immunoglobulins," <i>J. Mol. Biol.</i> , 196:901-917 (1987).
	Y	Chothia et al., "Conformations of immunoglobulin hypervariable regions," <i>Nature</i> , 342:877-883 (1989).
	Y	Chou et al., "Conformational parameters for amino acids in helical, $\beta$ -Sheet, and random coil regions calculated from proteins," <i>Biochemistry</i> , 13:211-222 (1974).
	Y	Chou et al., "Prediction of protein confirmation," <i>Biochemistry</i> , 13:222-245 (1974).
	Y	Coligan et al., eds., <i>Current Protocols in Immunology</i> , Vols. 1, 2, and 3, John Wiley & Sons, Inc., (1997) TABLE OF CONTENTS.
	Y	Condit et al., "Studies on the folic acid vitamins," <i>Cancer</i> , 13:222-249 (1960).
	Y	Dinarello et al., "Overview of interleukin-18: more than an interferon- $\gamma$ inducing factor," <i>J. Leukocyte Biol.</i> , 63:658-664 (1998).
	Y	Dürkop et al., "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease," <i>Cell</i> , 68:421-427 (1992).
	Y	Du Pasquier, "Evolution of the Immune System," <i>Fundamental Immunology</i> , Second Edition, Paul, ed., Raven Press, Ch. 7, p. 139-165 (1989).
	Y	Ellison et al., "The nucleotide sequence of a human immunoglobulin C $\gamma$ 1 gene," <i>Nucl. Acids Res.</i> , 10:4071-9 (1982).
	Y	Eppstein et al., "Biological activity of liposome-encapsulated murine interferon $\gamma$ is mediated by a cell membrane receptor," <i>Proc. Natl. Acad. Sci. USA</i> , 82:3688-3692 (1985).
	Y	Evans et al., "Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists," <i>J. Med. Chem.</i> , 30:1229-1239 (1987).
	Y	Evans, "Methotrexate," <i>Applied Pharmacokinetics</i> , Evans, ed., Ch. 16 pp. 518-548 (1980).
	Y	Faggioni et al., "Leptin-deficient ( <i>ob/ob</i> ) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor $\alpha$ and IL-18," <i>Proc. Natl. Acad. Sci. USA</i> , 97:2367-2372 (2000).
	Y	Farrar et al., "The molecular cell biology of interferon- $\gamma$ and its receptor," <i>Annu. Rev. Immunol.</i> , 11:571-611 (1993).
	Y	Fauchère, "Elements for the rational design of peptide drugs," <i>Adv. Drug Res.</i> , 15:29-69 (1986).
	Y	Freeman, "The flourometric measurement of the absorption, distribution and excretion of single doses of 4-amino-10-methyl pteroylglutamic acid (amethopterin) in man," <i>J. Pharmacol. Exp. Ther.</i> , 122:154-162 (1958).

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl.‡	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Freeman et al., "B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells," <i>J. Immunol.</i> , 143:2714-2722 (1989).
	Y	Freeman et al., "Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation," <i>Science</i> , 262:909-911 (1993).
	Y	Funauchi et al., "Serum level of interferon- $\gamma$ in autoimmune disease," <i>Tohoku J. Exp. Med.</i> , 164:259-267 (1991).
	Y	Furst, "Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritis," <i>J. Rheumatol. Suppl.</i> , 12:11-14 (1985).
	Y	Gennaro, ed., <i>Remington's Pharmaceutical Sciences</i> , 18 <sup>th</sup> Edition, Mack Publishing Company (1990) TABLE OF CONTENTS.
	Y	Gómez-Foix et al., "Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism," <i>J. Biol. Chem.</i> 267:25129-25134 (1992).
	Y	Grawunder et al., "Interferon- $\gamma$ arrests proliferation and causes apoptosis in stromal cell/interleukin-7-dependent normal murine pre-B cell lines and clones <i>in vitro</i> , but does not induce differentiation to surface immunoglobulin-positive B cells," <i>Eur. J. Immunol.</i> , 23:544-551 (1993).
	Y	Gribskov et al., "Profile analysis: detection of distantly related proteins," <i>Proc. Nat. Acad. Sci. USA</i> , 84:4355-4358 (1987).
	Y	Gribskov et al., "Profile analysis," <i>Meth. Enzym.</i> , 183:146-159 (1990).
	Y	Grosschedl et al., "Introduction of a $\mu$ immunoglobulin gene into the mouse germ line: specific expression in lymphoid cells and synthesis of functional antibody," <i>Cell</i> , 38: 647-658 (1984).
	Y	Hanahan, "Heritable formation of pancreatic $\beta$ -cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes," <i>Nature</i> , 315:115-122 (1985).
	Y	Harlow et al., <i>Antibodies: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press (1988) TABLE OF CONTENTS.
	Y	Haque et al., "Signal transduction in the interferon system," <i>Semin. Oncol.</i> , 25(suppl 1):14-22 (1998).
	Y	Henderson et al., "The metabolic fate of tritiated methotrexate," <i>Cancer Res.</i> , 25:1008-1017 (1965).
	Y	Herz et al., "Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice," <i>Proc. Natl. Acad. Sci.</i> 90:2812-2816 (1993).
	Y	Hoffmeister, "Methotrexate therapy in rheumatoid arthritis: 15 years experience," <i>Am. J. Med.</i> , 30:69-73 (1993).

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl.‡	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Holm et al., "Protein folds and families: sequence and structure alignments," <i>Nucl. Acid. Res.</i> , 27:244-247 (1999).
	Y	Hoogenboom et al., "By-passing immunization: Human antibodies from synthetic repertoires of germline V <sub>H</sub> gene segments rearranged <i>in vitro</i> ," <i>J. Mol. Biol.</i> , 227:381-388 (1992).
	Y	Isaacs et al., "Virus interference. I. The interferon," <i>Proc. R. Soc.</i> , 147:258-267 (1957).
	Y	Jaffe, "On the treatment of rheumatoid arthritis with M&Ms (Motrin & methotrexate)," <i>Arthritis and Rheumatism</i> , 31:299 (1988).
	Y	Jakobovits et al., "Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production," <i>Proc. Natl. Acad. Sci.</i> , 90:2551-2555 (1993).
	Y	Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial chromosome," <i>Nature</i> , 362:255-258 (1993).
	Y	Jolivet et al., "The pharmacology and clinical use of methotrexate," <i>N. Eng. J. Med.</i> , 309:1094-1104 (1983).
	Y	Jonasch et al. "Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities," <i>Oncologist</i> , 6:34-55 (2001).
	Y	Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> , 321:522-525 (1986).
	Y	Jones, "Progress in protein structure prediction," <i>Curr. Opin. Struct. Biol.</i> , 7:377-387 (1997).
	Y	Kabat et al., <i>Sequences of Proteins of Immunological Interest</i> , Fifth Edition, U.S. Department of Health and Human Services, (1991) TABLE OF CONTENTS.
	Y	Khare et al., "Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis," <i>J. Immunol.</i> , 155:3653-3659 (1995).
	Y	Khare et al., "Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role for B27 heavy chains and not B27-derived peptides," <i>J. Immunol.</i> , 160:101-106 (1998).
	Y	Khare et al., "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice," <i>Proc. Natl. Acad. Sci. USA</i> , 97:3370-3375 (2000).
	Y	Kranz et al., "Restricted reassociation of heavy and light chains from hapten-specific monoclonal antibodies," <i>Proc. Natl. Acad. Sci. USA</i> , 78:5807-5811 (1981).
	Y	Langer et al., "Biocompatibility of polymeric delivery systems for macromolecules," <i>J. Biomed. Mater. Res.</i> , 15:267-277 (1981).
	Y	Langer, "Controlled release of macromolecules," <i>ChemTech</i> , 12:98-105 (1982).

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl. <sup>‡</sup>	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Laughlin et al., "Cloning of infectious adeno-associated virus genomes in bacterial plasmids," <i>Gene</i> , 23:65-73 (1983).
	Y	LaPlanche et al., "Phosphorothioate-modified oligodeoxyribonucleotides. III. NMR and UV spectroscopic studies of the R <sub>p</sub> -R <sub>p</sub> , S <sub>p</sub> -S <sub>p</sub> and R <sub>p</sub> -S <sub>p</sub> duplexes, [d (GG <sub>s</sub> AATTCC)] <sub>2</sub> derived from diastereomeric O-ethyl phosphorothioates," <i>Nucl. Acids Res.</i> , 14:9081-9093 (1986).
	Y	Lesk, ed., <i>Computational Molecular Biology</i> , Oxford University Press (1988) TABLE OF CONTENTS.
	Y	Lewis et al., "Use of a novel mutagenesis strategy, optimized residue substitution, to decrease the off-rate of an anti-gp120 antibody," <i>Mol. Immunol.</i> , 32:1065-1072 (1995).
	Y	Lim et al., "Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products," <i>Ann. Rheum. Dis.</i> , 52:429-435 (1993).
	Y	Linsley et al., "Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation," <i>J Exp. Med.</i> , 173:721-730 (1991).
	Y	Liu et al., "Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells," <i>Proc. Natl. Acad. Sci. USA</i> , 84:3439-3443 (1987).
	Y	MacLennan et al., "Structure-function relationships in the Ca <sup>2+</sup> -binding and translocation domain of SERCA1: physiological correlates in Brody disease," <i>Acta Physiol. Scand. Suppl.</i> , 643:55-67 (1998).
	Y	Marks et al., "By-passing immunization: building high affinity human antibodies by chain shuffling," <i>Biotechnology</i> , 10:779-783 (1992).
	Y	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage," <i>J. Mol. Biol.</i> , 222:581-597 (1991).
	Y	Marston et al., "Solubilization of protein aggregates," <i>Meth. Enz.</i> , 182:264-276 (1990).
	Y	Masutani et al., "Predominance of Th1 immune response in diffuse proliferative lupus nephritis," <i>Arthritis &amp; Rheumatism</i> , 44:2097-2106 (2001).
	Y	Merlin et al., " <sup>125</sup> I-labelled human interferons alpha, beta and gamma: comparative receptor-binding data," <i>J. Gen. Virol.</i> , 66:1149-1152 (1985).
	Y	Miura et al., "Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40 <sup>tax</sup> ," <i>Mol. Cell Biol.</i> 11:1313:1325 (1991).
	Y	Morgan et al., "Folate status of rheumatoid arthritis patients receiving long-term, low dose methotrexate therapy," <i>Arthritis &amp; Rheumatism</i> , 30:1348-1356 (1987).

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl.‡	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Morrison et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. USA</i> , 81:6851-6855 (1984).
	Y	Moult, "The current state of art in protein structure prediction," <i>Curr. Opin. Biotech.</i> , 7:422-427 (1996).
	Y	Müller, "Determination of affinity and specificity of anti-hapten antibodies by competitive radioimmunoassay," <i>Meth. Enzymol.</i> , 92:589-601 (1983).
	Y	Nabozny et al., "Identification of a cyanogen bromide fragment of porcine type II collagen capable of modulating collagen arthritis in B10.RIII(H-2 <sup>f</sup> ) mice," <i>Autoimmunity</i> , 20:39-49 (1995).
	Y	Nakashima et al., "The combination of polymorphisms within interferon- $\gamma$ receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus," <i>FEBS Lett.</i> , 453:187-190 (1999).
	Y	Narumi et al., "Serum levels of INF-inducible protein-10 relating to the activity of systemic lupus erythematosus," <i>Cytokine</i> , 12:1561-1565 (2000).
	Y	Neuberger et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> , 312:604-608 (1984).
	Y	Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function," <i>Nature</i> , 314:268-270 (1985).
	Y	Novelli et al., "Environmental signals influencing expression of the IFN- $\gamma$ receptor on human T cells control whether IFN- $\gamma$ promotes proliferation or apoptosis," <i>J. Immunol.</i> 152:496-504 (1994).
	Y	Perhala et al., "Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate," <i>Arthritis and Rheumatism</i> , 34:146-152 (1991).
	Y	Pestka, "The human interferon-alpha species and hybrid proteins," <i>Seminars Oncol.</i> , 24:S9-4-S9-17 (1997).
	Y	Pfeffer et al., "Biological properties of recombinant $\alpha$ -interferons: 40 <sup>th</sup> anniversary of the discovery of interferons," <i>Cancer Res.</i> , 58: 2489-2499 (1998).
	Y	Readhead et al., "Expression of a myelin basic protein gene in transgenic shiverer mice: correction of the dysmyelinating phenotype," <i>Cell</i> , 48:703-712 (1987).
	Y	Riechmann et al., "Reshaping human antibodies for therapy," <i>Nature</i> , 332:323-327 (1988).
	Y	Rodenhuis et al., "Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate," <i>Arthritis and Rheumatism</i> , 30:369-374 (1987).

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl. <sup>‡</sup>	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Rojas et al., "Inhibition of apoptotic cell death in B-CLL by interferon gamma correlates with clinical stage," <i>Leukemia</i> , 10:1782-1788 (1996).
	Y	Rozzo et al., "Evidence for an interferon-inducible gene, <i>Ifi202</i> , in the susceptibility to systemic lupus," <i>Immunity</i> , 15:435-443 (2001).
	Y	Sambrook et al., <i>Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press (1989) TABLE OF CONTENTS.
	Y	Samsonov et al., "Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus," <i>Lupus</i> , 4:29-32 (1995).
	Y	Sasaki et al., "Structure-mutation analysis of the ATPase site of <i>Dictyostelium discoideum</i> myosin II," <i>Adv. Biophys</i> , 35:1-24 (1998).
	Y	Schindler et al., "Transcriptional responses to polypeptide ligands: the JAK-STAT pathway," <i>Annu. Rev. Biochem</i> , 64:621-651 (1995).
	Y	Seeger et al., "Analogs of pteroylglutamic acid. III. 4-Amino derivatives," <i>J. Am. Chem. Soc.</i> , 71: 1753-1755 (1949).
	Y	Segal et al., "Methotrexate: mechanism of action in rheumatoid arthritis," <i>Seminars in Arthritis and Rheumatism</i> , 20:190-198 (1990).
	Y	Seitz et al., "Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells," <i>Br. J. Rheumatology</i> , 34:602-609 (1995).
	Y	Sidman et al., "Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid," <i>Biopolymers</i> , 22:547-556 (1983).
	Y	Smith et al., "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins," <i>Science</i> , 248:1019-1023 (1990).
	Y	Smith, ed., <i>Biocomputing: Informatics and Genome Projects</i> , Academic Press (1994) TABLE OF CONTENTS.
	Y	Sperling et al., "Acute and chronic suppression of leukotriene B <sub>4</sub> synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate," <i>Arthritis and Rheumatism</i> , 35:376-384 (1992).
	Y	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," <i>EMBO J.</i> , 8:1403-1410 (1989).
	Y	Ternowitz et al., "Methotrexate inhibits the human C5a-induced skin response in patients with psoriasis," <i>J. Inv. Derm.</i> , 89:192-196 (1987).
	Y	Theofilopoulos et al., "Murine models of systemic lupus erythematosus," <i>Adv. Immunol.</i> , 37:269-390 (1985).

‡ Copies of U.S. Patent publications are not included.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl.‡	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Theofilopoulos et al., "The role of IFN- $\gamma$ in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity," <i>Arthritis Res.</i> 3:136-141 (2001).
	Y	Uhlmann et al., "Antisense oligonucleotides: a new therapeutic principle," <i>Chemical Reviews</i> , 90: 543-584 (1990).
	Y	Van de Kerkhof et al., "Methotrexate inhibits the leukotriene B <sub>4</sub> induced intraepidermal accumulation of polymorphonuclear leukocytes," <i>Brit. J. Derm.</i> , 113:251a-255a (1985).
	Y	Veber et al., "The design of metabolically-stable peptide analogs," <i>TINS</i> , 8: 392-396 (1985).
	Y	Verhoeven et al., "Reshaping human antibodies: grafting an antilysozyme activity," <i>Science</i> , 239: 1534-1536 (1988).
	Y	von Bülow et al., "NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily," <i>Science</i> , 278:138-140 (1997).
	Y	Vyse et al., "Genetic susceptibility to systemic lupus erythematosus," <i>Ann. Rev. Immunol.</i> , 16:261-292 (1998).
	Y	Wahl et al., "Improved radioimaging and tumor localization with monoclonal F(ab') <sub>2</sub> ," <i>J. Nucl. Med.</i> , 24:316-325 (1983).
	Y	Weinblatt et al., "Efficacy of low-dose methotrexate in rheumatoid arthritis," <i>N. Eng. J. Med.</i> , 312:818-822 (1985).
	Y	Williams et al., "Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis," <i>Arthritis Rheum.</i> , 28:721-730 (1985).
	Y	Yokoyama et al., "Up-regulated MHC-class II expression and $\gamma$ -IFN and soluble IL-2R in lupus nephritis," <i>Kidney Int.</i> , 42:755-763 (1992)
	Y	Zon et al., "Phosphorothioate oligonucleotides," <i>Oligonucleotides and Analogues: A Practical Approach</i> , Eckstein, ed., Oxford University Press, Ch. 4, p. 87-108 (1991).

Examiner	Date Considered
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

‡ Copies of U.S. Patent publications are not included.